cervical carcinoma
Conditions
Interventions
B:SpaceRTC implantation
Sponsors
SCIENCES ZHEJIANG CANCER HOSPITAL
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Confirmed cervical cancer through pathological examination, plan to use intensity modulated radiotherapy (IMRT) combined with three-dimensional close range radiotherapy for root canal treatment Patients undergoing therapeutic radiotherapy and concurrent chemotherapy; 2. Karst score = 70 points; 3. Female patients; Age = 18 years old, = 75 years old; 4. There are no metal implants in the pelvic cavity or joints, and they can withstand MRI examination; 5. No contraindications for CT scanning; 6. Able to understand the purpose of the experiment, voluntarily participate and sign an informed consent form.
Exclusion criteria
Exclusion criteria: 1. Previously received pelvic radiation therapy; 2. Previously received treatment for the target tumor (surgery, chemotherapy, immunotherapy, targeted drugs); 3. History of other malignant tumors within the past 5 years (excluding malignant tumors that have undergone radical surgery, such as complete resection)Basal cell carcinoma, in situ carcinoma, etc; 4. According to the researcher's judgment, the subject has contraindications to radiotherapy; 5. There is an infection at the injection site, or there is active inflammation or infection in the surrounding tissues or organs that may affect the injection site Injection safety; 6. According to the researcher's judgment, the tumor invades the injection site and may affect the injection process and injection safety; 7. Known to be allergic to the ingredients of the test product, known to be allergic to iodinated contrast agents, known to have a history of severe allergic reactions or allergies History of sexual shock; 8. Untreated hyperthyroidism; 9. Have a history of inflammatory bowel disease (such as ulcerative colitis, Crohn's disease); 10. Existence of active hemorrhagic disease (excluding vaginal bleeding related to the target tumor), or platelet count less than50 × 10^9/L; 11. Individuals with severe mental illness, cognitive impairment, and cognitive impairment; 12. Those who have participated in clinical trials of other medical devices or drugs within one month before signing the informed consent form; 13. Pregnant women, lactating women, or those who plan to conceive during the study period; 14. Other circumstances in which the researcher determines that the subject is not suitable to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accumulated dose of rectal D2cc for close range radiotherapy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluation of cumulative dose for rectal D0.1cc, D5cc, and efficacy of sigmoid colon/small intestine/bladder D0.1cc, D2cc, and D5cc in close range radiotherapy;Success rate of hydrogel implantation;Stability of hydrogel;Image quality evaluation of hydrogel imaging;QLQ-C30 rating;QLQ-CX24 rating;Equipment performance evaluation; | — |
Countries
China
Contacts
Public ContactXiang Zhang
SCIENCES ZHEJIANG CANCER HOSPITAL
Outcome results
None listed